Naval Daver, MD, of the University of Texas MD Anderson Cancer Center, Houston, TX, gives an overview of current T-cell based immunotherapies for the treatment of acute myeloid leukemia (AML), as well as future developments in AML management. There are various therapies that utilize T-cells, including chimeric antigen receptor (CAR) T-cell therapy, bispecific and dual antigen receptor-targeting antibodies, and T-cell immune checkpoint inhibitors. Dr Daver also talks on the difficulties faced during the development of T-cell based immunotherapies and outlines the encouraging results demonstrated by agents targeting components of the innate immune system. This interview took place during the ninth annual meeting of the Society of Hematologic Oncology (SOHO 2021) congress.
Naval Daver, MD, has received research funding from Daiichi-Sankyo, Bristol-Myers Squibb, Pfizer, Gilead, Sevier, Genentech, Astellas, Daiichi-Sankyo, Abbvie, Hanmi, Trovagene, FATE therapeutics, Amgen, Novimmune, Glycomimetics, Trillium, and ImmunoGen and has served in a consulting or advisory role for Daiichi-Sankyo, Bristol-Myers Squibb, Arog, Pfizer, Novartis, Jazz, Celgene, AbbVie, Astellas, Genentech, Immunogen, Servier, Syndax, Trillium, Gilead, Amgen, Shattuck labs, and Agios.